Table 4. Historical controls for progression-free survival for each cohort.
Cohort | Biliary Tract Cancer | Bladder Cancer (CrCl: ≥ 60 mL/min and ECOG PS 0,1; fit) | Bladder Cancer (CrCl: ≥ 30 to < 60 mL/min and/or ECOG PS 2; unfit) | Squamous NCSLC |
---|---|---|---|---|
Historical median PFS duration | 8.8 months | 7.6 months | 5.8 months | 5 months |
Abbreviations: CrCl, creatinine clearance; ECOG, Eastern Cooperative Oncology Group; NSCLC, non-small cell lung cancer; PFS, progression-free survival; PS, performance status.